Sosei finds its R&D engine
How Japan's Sosei plans to turn Heptares into its R&D engine
Sosei Group Corp. has only one clinical candidate in development, but the Japanese biotech may have found its R&D engine in drug discovery platform company Heptares Therapeutics Ltd. The M&A deal marks a clean break from Sosei's recent history as a reprofiling company and, according to founder, Chairman and CEO Shinichi Tamura, should make the company globally competitive as a pure play biotech developing innovative molecules against GPCR targets.
Sosei last week said it would acquire Heptares for $180 million up front and up to $220 million in milestones. Tamura said the most important asset is Heptares' StaR drug discovery technology, which stabilizes GPCRs in their functional forms, allowing for isolation and purification